Team

Marta Barrachina

CEO
CO-FOUNDER

PhD in Biochemistry (University of Barcelona) and Executive MBA (La Salle – Ramon Llull University).

Specialist in gene regulation and epigenetics in neurodegenerative and neurological diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and Schizophrenia. Author of 38 scientific articles published in international journals related to neurosciences, h index equal to 22, and inventor of 9 patents. Miguel Servet researcher (Institute of Health Carlos III - ISCIII) in 2008, she holds a permanent position in IDIBELL as principal investigator. She has leaded several national and private competitive projects in the last 16 years (Institute of Neuropathology – Bellvitge Hospital – IDIBELL). She has directed three doctoral thesis and five experimental masters. Member of the Scientific Review Board at the Alzheimer's Drug Discovery Foundation.

Ramón Reñé

Medical Advisory Board
CO-FOUNDER

Head of Functional Dementia Unit in Bellvitge University Hospital. He has large experience in the treatment of patients with Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Degeneration and Dementia with Lewy Bodies. He has leaded more than ten clinical trials in the last five years in collaboration with pharmaceutical companies (GSK, Sanofi, Noscira, Servier, Grifols, Lundbeck, Astra Zeneca, Eli Lilly, Biogen and Roche). Moreover, he has also been focused on caregivers, maintaining a tight vinculation with Alzheimer’s familiar Associations.

Jordi Gascón

Medical Advisory Board
CO-FOUNDER

Neurologist specialist in Dementia and Neurometabolic diseases in the Functional Dementia Unit of Bellvitge University Hospital. Associate professor in Morphological Sciences in Autonomous University of Barcelona. Expert in the management and treatment of Mild cognitive impairment and Dementias: Alzheimer’s disease, Dementia with Lewy Bodies, Frontotemporal Dementia and Amyotrophic lateral Sclerosis with cognitive or behavioural impairment. He is a reference neurologist for the treatment of Niemann-Pick C in the adult. Large experience in clinical trials with pharmaceutical companies in the last ten years and as a consultant at his hospital.

Lidia Casas

Patent Attorney

Lídia is Qualified European Patent Attorney (EQE-2014) and has a degree in Biochemistry. She is a professional with 19 years experience in Intellectual Property, especially in the fields of biotechnology, biomedicine and medtech. She created her own project of patent consultancy particularly for start-up companies, Patent Riders. Lídia works for ADmit Therapeutics as external IP Manager, managing all the aspects of IP of the company.